Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
Feasibility Study of mFOLFOX6 in Patients With Advanced Colorectal Cancer
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2006-04-21
- Lead Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
- Target Recruit Count
- 30
- Registration Number
- NCT00209703
- Locations
- 🇯🇵
Hokkaido University Hospital (Hokkaido University Graduate School of Medicine), Sapporo, Hokkaido, Japan
Phase I / II Study of Irinotecan (CPT-11) Combined With l-Leucovorin (l-LV) and 5-FU in Patients With Advanced Colorectal Cancer
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2005-09-21
- Lead Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
- Target Recruit Count
- 23
- Registration Number
- NCT00209625
- Locations
- 🇯🇵
Hokkaido University Hospital, Sapporo, Hokkaido, Japan
Phase I/II Study of Taxotere,CDDP and 5-FU(TPF) in Pre-treated Pts With Metastatic Esophageal Cancer.
- Conditions
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2010-05-26
- Lead Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
- Target Recruit Count
- 30
- Registration Number
- NCT00209716
- Locations
- 🇯🇵
・ Hokkaido University Hospital (Hokkaido University Graduate School of Medicine), Sapporo, Hokkaido, Japan
Phase I/II Study of TPF as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer.
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2010-05-26
- Lead Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
- Target Recruit Count
- 30
- Registration Number
- NCT00209690
- Locations
- 🇯🇵
・ Hokkaido University Hospital (Hokkaido University Graduate School of Medicine / School of Medicine), Sapporo, Hokkaido, Japan
Phase I Trial of huA33 Plus Chemotherapy in Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 20
- Registration Number
- NCT00199797
- Locations
- 🇨🇭
UniversitaetsSpital Zuerich, Zurich, Switzerland
🇩🇪Krankenhaus Nordwest, Frankfurt, Germany
Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-06-22
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 50
- Registration Number
- NCT00193284
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Chemotherapy With or Without Surgical Resection in Locally Advanced Esophageal Cancer
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 200
- Registration Number
- NCT00193141
Weekly Docetaxel and CMF in the Adjuvant Treatment of Elderly Women With High-Risk Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 150
- Registration Number
- NCT00193011
Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 36
- Registration Number
- NCT00193219
- Locations
- 🇺🇸
St. Louis Cancer Care, Chesterfield, Missouri, United States
🇺🇸Jackson Oncology Associates, Jackson, Mississippi, United States
🇺🇸Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, United States
Advanced Oesophageal Cancer Study to Compare Quality of Life and Palliation of Dysphagia.
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2017-07-12
- Lead Sponsor
- Trans Tasman Radiation Oncology Group
- Target Recruit Count
- 220
- Registration Number
- NCT00193882
- Locations
- 🇦🇺
Royal North Shore Hospital, Sydney, New South Wales, Australia
🇦🇺Prince of Wales Hospital, Randwick, New South Wales, Australia
🇦🇺Premion - Wesley, Auchenflower, Queensland, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.